BREAKINGتازہ ترینताज़ा खबर
Ecuador Fishermen Sue Trump Over US Boat StrikesEcuador Fishermen Sue Trump Over US Boat StrikesEcuador Fishermen Sue Trump Over US Boat StrikesIsrael Divided Over Possible New Iran StrikeIsrael Divided Over Possible New Iran StrikeIsrael Divided Over Possible New Iran StrikeRandy Travis Given 1% Chance Before ComebackRandy Travis Given 1% Chance Before ComebackRandy Travis Given 1% Chance Before ComebackFitness Coach in ICU With Meningitis After Bali HeadacheFitness Coach in ICU With Meningitis After Bali HeadacheFitness Coach in ICU With Meningitis After Bali Headache800,000 Young Pakistanis Chose Exit Over Protest800,000 Young Pakistanis Chose Exit Over Protest800,000 Young Pakistanis Chose Exit Over ProtestTrump May Hold Off Iran Attacks, Sources SayTrump May Hold Off Iran Attacks, Sources SayTrump May Hold Off Iran Attacks, Sources Say8 College Football Games Moved After Ground Stop8 College Football Games Moved After Ground Stop8 College Football Games Moved After Ground Stop6,600 US Flights Cancelled in Nationwide Ground Stop6,600 US Flights Cancelled in Nationwide Ground Stop6,600 US Flights Cancelled in Nationwide Ground StopFederalist Society Ready to Move On From TrumpFederalist Society Ready to Move On From TrumpFederalist Society Ready to Move On From TrumpCanberra Targets 30% More ASEAN Students by 2030Canberra Targets 30% More ASEAN Students by 2030Canberra Targets 30% More ASEAN Students by 2030El-Sayed: Stop Funding Foreign Armies With US TaxesEl-Sayed: Stop Funding Foreign Armies With US TaxesEl-Sayed: Stop Funding Foreign Armies With US TaxesCalifornia Democrats Probe Trump, Hold Off ImpeachmentCalifornia Democrats Probe Trump, Hold Off ImpeachmentCalifornia Democrats Probe Trump, Hold Off ImpeachmentWindows 11's New Run Box Arrives for All in DecemberWindows 11's New Run Box Arrives for All in DecemberWindows 11's New Run Box Arrives for All in DecemberRogan: Nunes Has Huge Striking Edge Over HarrisonRogan: Nunes Has Huge Striking Edge Over HarrisonRogan: Nunes Has Huge Striking Edge Over HarrisonStatins After 70: Stopping Them Raises Heart RiskStatins After 70: Stopping Them Raises Heart RiskStatins After 70: Stopping Them Raises Heart RiskNew Congress May Doubt Trump's Tough Cuba PolicyNew Congress May Doubt Trump's Tough Cuba PolicyNew Congress May Doubt Trump's Tough Cuba PolicyLHC Forms Larger Bench on PTI Symbol PleaLHC Forms Larger Bench on PTI Symbol PleaLHC Forms Larger Bench on PTI Symbol PleaNearly $20M Found in Hungary Corruption ProbeNearly $20M Found in Hungary Corruption ProbeNearly $20M Found in Hungary Corruption ProbeCybertruck Fans in Mourning, Demand Musk AnswersCybertruck Fans in Mourning, Demand Musk AnswersCybertruck Fans in Mourning, Demand Musk AnswersColorado Stuns No. 14 Houston 42-32 in UpsetColorado Stuns No. 14 Houston 42-32 in UpsetColorado Stuns No. 14 Houston 42-32 in UpsetEcuador Fishermen Sue Trump Over US Boat StrikesEcuador Fishermen Sue Trump Over US Boat StrikesEcuador Fishermen Sue Trump Over US Boat StrikesIsrael Divided Over Possible New Iran StrikeIsrael Divided Over Possible New Iran StrikeIsrael Divided Over Possible New Iran StrikeRandy Travis Given 1% Chance Before ComebackRandy Travis Given 1% Chance Before ComebackRandy Travis Given 1% Chance Before ComebackFitness Coach in ICU With Meningitis After Bali HeadacheFitness Coach in ICU With Meningitis After Bali HeadacheFitness Coach in ICU With Meningitis After Bali Headache800,000 Young Pakistanis Chose Exit Over Protest800,000 Young Pakistanis Chose Exit Over Protest800,000 Young Pakistanis Chose Exit Over ProtestTrump May Hold Off Iran Attacks, Sources SayTrump May Hold Off Iran Attacks, Sources SayTrump May Hold Off Iran Attacks, Sources Say8 College Football Games Moved After Ground Stop8 College Football Games Moved After Ground Stop8 College Football Games Moved After Ground Stop6,600 US Flights Cancelled in Nationwide Ground Stop6,600 US Flights Cancelled in Nationwide Ground Stop6,600 US Flights Cancelled in Nationwide Ground StopFederalist Society Ready to Move On From TrumpFederalist Society Ready to Move On From TrumpFederalist Society Ready to Move On From TrumpCanberra Targets 30% More ASEAN Students by 2030Canberra Targets 30% More ASEAN Students by 2030Canberra Targets 30% More ASEAN Students by 2030El-Sayed: Stop Funding Foreign Armies With US TaxesEl-Sayed: Stop Funding Foreign Armies With US TaxesEl-Sayed: Stop Funding Foreign Armies With US TaxesCalifornia Democrats Probe Trump, Hold Off ImpeachmentCalifornia Democrats Probe Trump, Hold Off ImpeachmentCalifornia Democrats Probe Trump, Hold Off ImpeachmentWindows 11's New Run Box Arrives for All in DecemberWindows 11's New Run Box Arrives for All in DecemberWindows 11's New Run Box Arrives for All in DecemberRogan: Nunes Has Huge Striking Edge Over HarrisonRogan: Nunes Has Huge Striking Edge Over HarrisonRogan: Nunes Has Huge Striking Edge Over HarrisonStatins After 70: Stopping Them Raises Heart RiskStatins After 70: Stopping Them Raises Heart RiskStatins After 70: Stopping Them Raises Heart RiskNew Congress May Doubt Trump's Tough Cuba PolicyNew Congress May Doubt Trump's Tough Cuba PolicyNew Congress May Doubt Trump's Tough Cuba PolicyLHC Forms Larger Bench on PTI Symbol PleaLHC Forms Larger Bench on PTI Symbol PleaLHC Forms Larger Bench on PTI Symbol PleaNearly $20M Found in Hungary Corruption ProbeNearly $20M Found in Hungary Corruption ProbeNearly $20M Found in Hungary Corruption ProbeCybertruck Fans in Mourning, Demand Musk AnswersCybertruck Fans in Mourning, Demand Musk AnswersCybertruck Fans in Mourning, Demand Musk AnswersColorado Stuns No. 14 Houston 42-32 in UpsetColorado Stuns No. 14 Houston 42-32 in UpsetColorado Stuns No. 14 Houston 42-32 in Upset
Advertisement
Text size:
Business • 2026-11-05, 13:24 GMT • ~1 min read

Servier's $1.55 billion muscular dystrophy drug fails its pivotal trial

Servier's $1.55 billion muscular dystrophy drug fails its pivotal trial

Servier's $1.55 billion muscular dystrophy drug fails its pivotal trial

Servier's $1.55 billion muscular dystrophy drug fails its pivotal trial

Key points

اہم نکات

मुख्य बातें

  • French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy.
  • In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals.
  • Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile.
  • French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy.
  • In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals.
  • Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile.
  • French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy.
  • In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals.
  • Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile.

French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy. In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals. Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile. The failure also raises questions about sevasemten's ongoing trial in Duchenne muscular dystrophy, a more severe form of the disease.

French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy. In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals. Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile. The failure also raises questions about sevasemten's ongoing trial in Duchenne muscular dystrophy, a more severe form of the disease.

French drugmaker Servier has suffered a major setback five months after paying $1.55 billion for Edgewise Therapeutics' muscular dystrophy business, after its drug sevasemten failed a pivotal trial in Becker muscular dystrophy. In the 18-month GRAND CANYON study of 175 adults, patients taking the daily oral drug did no better than those on placebo on the North Star Ambulatory Assessment, a scale measuring walking, standing and climbing stairs, and the trial also missed its secondary goals. Servier said the results did not match earlier, smaller studies and it is now analysing the full data; the drug kept a favourable safety profile. The failure also raises questions about sevasemten's ongoing trial in Duchenne muscular dystrophy, a more severe form of the disease.

Most read

سب سے زیادہ پڑھی گئی

सबसे ज़्यादा पढ़ी गई

  1. Loading...
Advertisement